Artwork

Content provided by Alex Jani: interviewing visionaries of healthcare innovation. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alex Jani: interviewing visionaries of healthcare innovation or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Reproducing Human Cancer Ecosystem to Deliver Cancer Drugs Faster: Dr. Marie-Agnès Doucey, Calico Biosystems

55:16
 
Share
 

Manage episode 430315881 series 3469528
Content provided by Alex Jani: interviewing visionaries of healthcare innovation. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alex Jani: interviewing visionaries of healthcare innovation or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Do you know what is the % of drug candidates that fail in human trials?

Guess, and I bet you underestimated it.

This is what we speak at the beginning of this episode and what my guest wants to change dramatically.

You will also hear about:

  • the % of patients that actually benefit from approved cancer drug therapies (spoiler: so so low)
  • cancer monotherapies vs. cancer combination therapies
  • how to reproduce the human cancer ecosystem from a tumor
  • precision oncology
  • multiomics analysis
  • and how to bring cancer drugs faster to patients

Dr. Marie-Agnès Doucey, the co-founder of Calico Biosystems, is a biotechnology engineer with a PhD in biochemistry. She has over 15 years of experience in R&D and drug development programs in oncology.

Calico Biosystems is a Swiss startup developing a drug testing platform that uses patients’ tumors, multiomics profiling, and computational modeling to predict the clinical efficacy of anti-cancer drugs at the pre-clinical stage. Radically accelerating drug development.

https://calicobiosystems.com/
If you've enjoyed listening, you'll make us happy by clicking "Follow" on X-Health.show and leaving a review.
The information in this podcast is for informational purposes only and should not be considered medical advice. If you have any medical questions, please consult your healthcare practitioner. The opinions on the show are Alex's or her guests. The podcast does not make any responsibility or warranties about guests statements or credibility. While the podcast makes every effort to ensure that the information shared is accurate, please let us know if you have any comments, suggestions or corrections.

  continue reading

Chapters

1. Dr. Marie-Agnès Doucey and Calico Biosystems (00:00:00)

2. Why Only 10% of Cancer Patients Benefit from Therapies (00:01:15)

3. Complexity of Experimental Oncology (00:09:00)

4. Cancer Monotherapies vs. Cancer Combination Therapies (00:12:50)

5. How to Reproduce Human Cancer Ecosystem (00:15:11)

6. What is Precision Oncology (00:17:10)

7. Platform for Cancer Drug Developers Instead of Animal Models (00:20:35)

8. Collaboration with the University of Lausanne (00:32:34)

9. What is Multiomics Analysis (00:37:49)

10. De-risking Clinical Studies and Moving to the Clinical Stage (00:40:35)

11. More Than a Decade of Research to Found a Startup (00:47:16)

12. Thank You, Follow Calico Biosystems (00:53:07)

13. Follow X-Health.show, Disclaimer (00:53:55)

68 episodes

Artwork
iconShare
 
Manage episode 430315881 series 3469528
Content provided by Alex Jani: interviewing visionaries of healthcare innovation. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alex Jani: interviewing visionaries of healthcare innovation or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Do you know what is the % of drug candidates that fail in human trials?

Guess, and I bet you underestimated it.

This is what we speak at the beginning of this episode and what my guest wants to change dramatically.

You will also hear about:

  • the % of patients that actually benefit from approved cancer drug therapies (spoiler: so so low)
  • cancer monotherapies vs. cancer combination therapies
  • how to reproduce the human cancer ecosystem from a tumor
  • precision oncology
  • multiomics analysis
  • and how to bring cancer drugs faster to patients

Dr. Marie-Agnès Doucey, the co-founder of Calico Biosystems, is a biotechnology engineer with a PhD in biochemistry. She has over 15 years of experience in R&D and drug development programs in oncology.

Calico Biosystems is a Swiss startup developing a drug testing platform that uses patients’ tumors, multiomics profiling, and computational modeling to predict the clinical efficacy of anti-cancer drugs at the pre-clinical stage. Radically accelerating drug development.

https://calicobiosystems.com/
If you've enjoyed listening, you'll make us happy by clicking "Follow" on X-Health.show and leaving a review.
The information in this podcast is for informational purposes only and should not be considered medical advice. If you have any medical questions, please consult your healthcare practitioner. The opinions on the show are Alex's or her guests. The podcast does not make any responsibility or warranties about guests statements or credibility. While the podcast makes every effort to ensure that the information shared is accurate, please let us know if you have any comments, suggestions or corrections.

  continue reading

Chapters

1. Dr. Marie-Agnès Doucey and Calico Biosystems (00:00:00)

2. Why Only 10% of Cancer Patients Benefit from Therapies (00:01:15)

3. Complexity of Experimental Oncology (00:09:00)

4. Cancer Monotherapies vs. Cancer Combination Therapies (00:12:50)

5. How to Reproduce Human Cancer Ecosystem (00:15:11)

6. What is Precision Oncology (00:17:10)

7. Platform for Cancer Drug Developers Instead of Animal Models (00:20:35)

8. Collaboration with the University of Lausanne (00:32:34)

9. What is Multiomics Analysis (00:37:49)

10. De-risking Clinical Studies and Moving to the Clinical Stage (00:40:35)

11. More Than a Decade of Research to Found a Startup (00:47:16)

12. Thank You, Follow Calico Biosystems (00:53:07)

13. Follow X-Health.show, Disclaimer (00:53:55)

68 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide